Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

247 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The incidence of invasive fungal infections in children, adolescents and young adults with acute lymphoblastic leukaemia/lymphoma treated with the UKALL2011 protocol: a multicentre retrospective study.
O'Reilly MA, Govender D, Kirkwood AA, Vora A, Samarasinghe S, Khwaja A, Grandage V, Rao A, Ancliff P, Pavasovic V, Cheng D, Carpenter B, Daw S, Hough R, O'Connor D. O'Reilly MA, et al. Br J Haematol. 2019 Jul;186(2):327-329. doi: 10.1111/bjh.15798. Epub 2019 Feb 15. Br J Haematol. 2019. PMID: 30768682 Free article. Clinical Trial. No abstract available.
Low seropositivity and suboptimal neutralisation rates in patients fully vaccinated against COVID-19 with B-cell malignancies.
Fox TA, Kirkwood AA, Enfield L, O'Reilly M, Arulogun S, D'Sa S, O'Nions J, Kavi J, Vitsaras E, Townsend W, Burns SO, Gohil SH, Cwynarski K, Thomson KJ, Noursadeghi M, Heyderman RS, Rampling T, Ardeshna KM, McCoy LE, Morris EC. Fox TA, et al. Br J Haematol. 2021 Dec;195(5):706-709. doi: 10.1111/bjh.17836. Epub 2021 Sep 21. Br J Haematol. 2021. PMID: 34545952 Free PMC article. No abstract available.
Early FDG-PET response predicts CAR-T failure in large B-cell lymphoma.
Kuhnl A, Roddie C, Kirkwood AA, Menne T, Cuadrado M, Marzolini MAV, Osborne W, Sanderson R, O'Reilly M, Townsend W, Benjamin R, Potter V, Patten PEM, Yallop D, Voo S, Petrides GS, Mulholland N, Kayani I. Kuhnl A, et al. Blood Adv. 2022 Jan 11;6(1):321-326. doi: 10.1182/bloodadvances.2021005807. Blood Adv. 2022. PMID: 34700342 Free PMC article. No abstract available.
Severe presentations and high mortality from SARS-CoV-2 in patients undergoing chimeric antigen receptor (CAR-T) therapy: a UK NCCP analysis.
Cheok KPL, Kirkwood AA, Menne T, Tholouli E, Chaganti S, Mathew A, Uttenthal B, Russell J, Irvine D, Johnson R, Nicholson E, Bazin J, Townsend W, Kuhnl A, O'Reilly M, Sanderson R, Patel A, Roddie C. Cheok KPL, et al. Leuk Lymphoma. 2022 Aug;63(8):1980-1984. doi: 10.1080/10428194.2022.2057487. Epub 2022 Apr 28. Leuk Lymphoma. 2022. PMID: 35481791 No abstract available.
A national service for delivering CD19 CAR-Tin large B-cell lymphoma - The UK real-world experience.
Kuhnl A, Roddie C, Kirkwood AA, Tholouli E, Menne T, Patel A, Besley C, Chaganti S, Sanderson R, O'Reilly M, Norman J, Osborne W, Bloor A, Lugthart S, Malladi R, Patten PEM, Neill L, Martinez-Cibrian N, Kennedy H, Phillips EH, Jones C, Sharplin K, El-Sharkawi D, Latif AL, Mathew A, Uttenthal B, Stewart O, Marzolini MAV, Townsend W, Cwynarski K, Ardeshna K, Ardavan A, Robinson K, Pagliuca A, Collins GP, Johnson R, McMillan A. Kuhnl A, et al. Br J Haematol. 2022 Aug;198(3):492-502. doi: 10.1111/bjh.18209. Epub 2022 Apr 29. Br J Haematol. 2022. PMID: 35485402
CD34+-selected stem cell boost can safely improve cytopenias following CAR T-cell therapy.
Mullanfiroze K, Lazareva A, Chu J, Williams L, Burridge S, Silva J, Chiesa R, Rao K, Lucchini G, Ghorashian S, O'Reilly M, Carpenter B, Grandage V, Hough R, Roddie C, Amrolia PJ. Mullanfiroze K, et al. Blood Adv. 2022 Aug 23;6(16):4715-4718. doi: 10.1182/bloodadvances.2022007572. Blood Adv. 2022. PMID: 35790110 Free PMC article. No abstract available.
Addendum to British Society for Haematology Guideline for the management of mantle cell lymphoma, 2018 (Br. J. Haematol. 2018; 182: 46-62): Risk assessment of potential CAR T candidates receiving a covalent Bruton tyrosine kinase inhibitor for relapsed/refractory disease.
O'Reilly MA, Sanderson R, Wilson W, Iyengar S, Lambert J, McCulloch R, Eyre TA; BSH Guidelines Committee Haemato-oncology Task Force. O'Reilly MA, et al. Br J Haematol. 2022 Oct;199(1):40-44. doi: 10.1111/bjh.18378. Epub 2022 Jul 27. Br J Haematol. 2022. PMID: 35894253 No abstract available.
Effective bridging therapy can improve CD19 CAR-T outcomes while maintaining safety in patients with large B-cell lymphoma.
Roddie C, Neill L, Osborne W, Iyengar S, Tholouli E, Irvine D, Chaganti S, Besley C, Bloor A, Jones C, Uttenthal B, Johnson R, Sanderson R, Cheok K, Marzolini M, Townsend W, O'Reilly M, Kirkwood AA, Kuhnl A. Roddie C, et al. Blood Adv. 2023 Jun 27;7(12):2872-2883. doi: 10.1182/bloodadvances.2022009019. Blood Adv. 2023. PMID: 36724512 Free PMC article.
Outcome and feasibility of radiotherapy bridging in large B-cell lymphoma patients receiving CD19 CAR T in the UK.
Kuhnl A, Roddie C, Kirkwood AA, Chaganti S, Norman J, Lugthart S, Osborne W, Gibb A, Gonzalez Arias C, Latif A, Uttenthal B, Seymour F, Jones C, Springell D, Brady JL, Illidge T, Stevens A, Alexander E, Hawley L, O'Rourke N, Bedi C, Prestwich R, Frew J, Burns D, O'Reilly M, Sanderson R, Sivabalasingham S, Mikhaeel NG. Kuhnl A, et al. Br J Haematol. 2024 Aug;205(2):483-494. doi: 10.1111/bjh.19453. Epub 2024 Apr 9. Br J Haematol. 2024. PMID: 38594876
247 results